THE FDA IS HIRING SOMEONE TO READ YOUR DRUG POSTS — AND FILTER THEM BY AGE, SEX AND PERSONA
Notice number 37e4a5bc9a504c43ae9584e2512d83d3. Quotes due MONDAY. Period of performance 30 SEPTEMBER 2026 through 29 SEPTEMBER 2027.
The FDA wants a contractor to sit on TIKTOK, REDDIT and INSTAGRAM and capture, in the solicitation's own words, 'data on products, ingredients, claims, consumer conditions, sentiments, and other attributes' — sliced 'by age-group, sex, persona, and other attributes...using trained artificial intelligence (AI) modeling.'
PERSONA. That is the government's word, not mine, and it is a marketing word. It does not mean a person. It means a SEGMENT — the anxious 24-year-old who buys sleep gummies, the perimenopausal woman reading kratom threads at 2am. They are not building a case file. They are building an AUDIENCE MODEL.
And they named the vendor in the requirement: 'brand name or equal to BRIGHTFIELD GROUP online data subscription and analytic services.' Brightfield is a cannabis market-research firm. The FDA is not commissioning surveillance from scratch. It is BUYING A SUBSCRIPTION to a product the weed industry already pays for.
Stacked on top: a US Cannabis Consumer Survey of dispensary shoppers covering symptoms, purchase paths, dosages and medical conditions; a general-population survey covering cannabis, KRATOM, PSILOCYBIN and 'functional products'; and a women-focused survey segmented by fertility, perimenopause and postmenopause.
WHAT IT IS: the federal regulator building a listening post on the exact platforms where drug culture actually talks, and doing it through procurement rather than enforcement.
WHY IT MATTERS AND WHY IT IS NOT A CRACKDOWN STORY: the instinct is to file this as narcs-on-TikTok. That read is lazy and I think it is wrong. Read the stated purpose — 'address knowledge gaps on cannabis, cannabidiol (CBD), and emerging products' to inform 'policy, regulation, education, outreach, and compliance.' An agency that intends to BAN something does not need a persona-level sentiment model. An agency that intends to REGULATE something does, because regulation requires knowing what people actually take, why, and at what dose. The survey covering kratom and psilocybin alongside cannabis is the tell: those are not currently FDA-regulated consumer categories. You do not build a measurement instrument for a market you are not preparing to have an opinion about.
WHERE IT GOES: pair it with the rescheduling record closing this week and the shape is one thing — the machinery is being ASSEMBLED, quietly, by contract, while everyone watches the courts. Buying an existing industry data product is the sharpest detail. It means the government's picture of drug culture will be the INDUSTRY'S picture of drug culture, inheriting whatever that product already counts and already ignores. The bias goes in at procurement, not at analysis, and nobody will ever audit it because it arrived as a subscription line item.
THE CULTURAL READ: the underground's long-standing assumption is that posting is free — that the scene talks on platforms because platforms are ungoverned. This is a dated assumption and Monday is the deadline on the document that dates it.
NOT A MEASUREMENT — UNCALIBRATED, UNVALIDATED
